2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Recurrent Cancer
Recurrent cancer, the reappearance of cancer after a period of remission, poses a significant challenge in oncology. Despite initial treatments, cancer cells may persist undetected, eventually resurging. Addressing recurrence demands innovative approaches. Emerging therapies like immunotherapy harness the body's immune system to target cancer cells more effectively, potentially reducing recurrence rates. Precision medicine, tailoring treatment based on genetic profiles, offers promise in preventing relapse by identifying and targeting specific mutations driving cancer growth. Additionally, advances in early detection technologies, such as liquid biopsies capable of detecting minimal residual disease, hold potential in intercepting recurrence at its earliest stages. Combining these strategies with ongoing research into tumor microenvironments and cancer stem cells provides hope for more effective management of recurrent cancer in the future.
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China